PerkinElmer, Inc., a biotechnology company, on 25 December last year has launched a new range of assay kits utilizing AlphaLISA technology for improving the safety testing, manufacturing and quality control of biotherapeutic drugs.
"PerkinElmer is continuously seeking new ways to improve human health through the development of innovative technologies," said its President - Kevin Hrusovsky. "Adverse reactions due to drug toxicity are a real issue that we are passionate about helping to minimize. We are very excited to enable our customers to improve the safety and efficacy of new biotherapeutic drugs being developed through our new assay kits which are the latest addition to our growing biotherapeutics portfolio."
This kits use the AlphaLISA technology of PerkinElmer's to achieve higher quality results than the comparable ELISA (enzyme-linked immunosorbent assay) technology in half the time, for accelerating the drug discovery process, the company said.
AlphaLISA technology also has a protocol with fewer assay steps compared to standard ELISA, resulting in better inter-assay and intra-assay precision, improved coefficient of variations (CVs), and easier method transfer to downstream departments due to variability reduction.